PTGS2 and cancer: The analysis for cancer risk showed a significant association with any COX2 inhibitors use, although the OR (Table 3) was close to unity (OR 1.06, 95% CI 1.03–1.09, P<0.001), and no association for long-term use (OR 1.02, 95% CI 0.96–1.08, P=0.616).